▶ video
Ivonescimab Clears OS vs Keytruda; the Hazard Ratio Waits for WCLC
HARMONi-2's OS win over pembrolizumab is real but detail-light: SMMT +17.3% on 2.7x volume, Akeso +15.3% in two sessions — and the HR itself lands at WCLC this month.
Topic
#china-licensing
1 post